Novel immunotherapeutics for GBM and oligodendroglioma include cluster of differentiation 204 (CD204), S100A, and the CE7 epitope of the L1-CAM adhesion molecule [92,306,308]. This evidence concerns the gene MSR1 and glioblastoma.